Chilblains in immune-mediated inflammatory diseases: a review

被引:8
|
作者
Dubey, Shirish [1 ,2 ]
Joshi, Nilay [3 ]
Stevenson, Olivia [3 ]
Gordon, Caroline [4 ]
Reynolds, John A. [5 ,6 ]
机构
[1] Univ Oxford, Dept Rheumatol, Oxford Univ Hosp NHS FT, Oxford, England
[2] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England
[3] Kettering Gen Hosp NHS FT, Dept Rheumatol, Kettering, England
[4] Univ Birmingham, Rheumatol Res Grp, Inst Inflammat & Ageing IIA, Birmingham, W Midlands, England
[5] Univ Birmingham, John A Reynolds Rheumatol Res Grp, Inst Inflammat & Ageing IIA, Birmingham, W Midlands, England
[6] Sandwell & West Birmingham NHS Trust, Rheumatol Dept, Birmingham, W Midlands, England
关键词
Chilblains; chilblain lupus erythematosus; CHLE; immune-mediated inflammatory diseases; IMID; LUPUS-ERYTHEMATOSUS HUTCHINSON; AICARDI-GOUTIERES SYNDROME; CLINICAL CHARACTERISTICS; PERNIOSIS; NIFEDIPINE; EFFICACY; PLACEBO; MANIFESTATION; ASSOCIATION; ANTIBODIES;
D O I
10.1093/rheumatology/keac231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chilblains were first described over a hundred years ago as cutaneous inflammatory lesions, typically on the digits, occurring on cold exposure. Chilblains can be primary, or secondary to a number of conditions such as infections, including COVID-19, and immune-mediated inflammatory disorders (IMIDs) with SLE being the commonest. Chilblain lupus erythematosus (CHLE) was first described in 1888 as cold-induced erythematous lesions before the terms 'chilblains' or 'perniosis' were coined. Diagnostic criteria exist for both chilblains and CHLE. Histopathologically, CHLE lesions show interface dermatitis with perivascular lymphocytic infiltrate. Immunofluorescence demonstrates linear deposits of immunoglobulins and complement in the dermo-epidermal junction. This narrative review focuses on chilblains secondary to immune-mediated inflammatory disorders, primarily the epidemiology, pathogenesis and treatment of CHLE.
引用
收藏
页码:4631 / 4642
页数:12
相关论文
共 50 条
  • [1] Genetics of immune-mediated inflammatory diseases
    David, T.
    Ling, S. F.
    Barton, A.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01): : 3 - 12
  • [2] Adiponectin in inflammatory and immune-mediated diseases
    Fantuzzi, Giamila
    [J]. CYTOKINE, 2013, 64 (01) : 1 - 10
  • [3] Inflammatory and Immune-Mediated Cutaneous Diseases
    Quaresma, Juarez A. S.
    Sotto, Mirian N.
    Balato, Anna
    [J]. MEDIATORS OF INFLAMMATION, 2017, 2017
  • [4] Reframing Immune-Mediated Inflammatory Diseases
    Boutrid, Nada
    Rahmoune, Hakim
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21):
  • [5] Immune-mediated inflammatory diseases and psoriasis
    Delaporte, E.
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S269 - S274
  • [6] Immune monitoring and treatment in immune-mediated inflammatory diseases
    Femke van Wijk
    Marjolein de Bruin
    Helen Leavis
    Stefan Nierkens
    [J]. Nature Communications, 13
  • [7] Immune monitoring and treatment in immune-mediated inflammatory diseases
    van Wijk, Femke
    de Bruin, Marjolein
    Leavis, Helen
    Nierkens, Stefan
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [8] The influence of biologics on the microbiome in immune-mediated inflammatory diseases: A systematic review
    Ruszkowski, Jakub
    Daca, Agnieszka
    Szewczyk, Adrian
    Debska-Slizien, Alicja
    Witkowski, Jacek M.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2021, 141
  • [9] Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review
    Garcillan, Beatriz
    Salavert, Miguel
    Regueiro, Jose R.
    Diaz-Castroverde, Sabela
    [J]. VACCINES, 2022, 10 (02)
  • [10] Psychiatric comorbidity in immune-mediated inflammatory diseases
    Marrie, Ruth Ann
    Bernstein, Charles N.
    [J]. WORLD PSYCHIATRY, 2021, 20 (02) : 298 - 299